Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Pharmaceutical companies have been in talks with the U.S. government to figure out how to bring drug prices down after President Trump signed in May an executive order that ties U.S. prices to the ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.